文献速递胸部肿瘤消化系统肿瘤

KRAS G13C选择性抑制揭示 codon 13突变癌症对野生型RAS亚型的依赖增加

Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers.
PubMed 文献 · Cancer Discov · 2026-06-22

本研究报道口服RAS(ON) G13C选择性共价三复合物抑制剂RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退,但三分之一的KRAS G13C突变人癌细胞系体外显示RAS通路抑制不完全。Codon 13突变RAS稳定性降低、核苷酸交换增加且GTP水解增强,致癌性减弱,且常伴野生型RAS激活突变。RMC-8839与RAS(ON)多选择性抑制剂联用较单药更深抑制肿瘤生长。

要点

  • RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退
  • 三分之一KRAS G13C突变细胞系体外RAS通路抑制不完全
  • RMC-8839联合RAS(ON)多选择性抑制剂较单药更深抑制肿瘤生长

核心结论

  • KRAS G13C突变癌症对野生型RAS(ON)信号依赖增加,联合RAS(ON)多选择性抑制剂可增强疗效。

研究设计与样本

  • 临床前研究:使用KRAS G13C突变异种移植模型和人癌细胞系评估RMC-8839及联合RAS(ON)多选择性抑制剂的疗效与通路抑制。

主要发现

  • RMC-8839在部分KRAS G13C突变异种移植模型中诱导肿瘤消退。
  • 三分之一的KRAS G13C突变人癌细胞系体外显示RAS通路抑制不完全,尽管KRAS G13C近完全结合。
  • Codon 13突变RAS稳定性降低、核苷酸交换增加、内在及GAP刺激的GTP水解增强,致癌性减弱。
  • Codon 13突变肿瘤中富集导致野生型RAS激活增加的共发RAS通路突变。
  • RMC-8839联合RAS(ON)多选择性抑制剂较任一单药更深抑制KRAS G13C突变异种移植肿瘤生长。

临床怎么用

  • KRAS G13C突变癌症可能需联合RAS(ON)多选择性抑制剂以克服野生型RAS代偿。

局限性

  • 研究为临床前体外和异种移植模型,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Covalent KRAS G12C inhibitors have changed the treatment landscape for NSCLC and CRC patients, but numerous RAS-mutant cancers lack approved targeted therapies. Here we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tri-complex inhibitor that induced tumor regressions in selected KRAS G13C-mutant xenograft models. However, one-third of KRAS G13C-mutant human cancer cell lines in vitro showed incomplete RAS pathway suppression despite near-complete KRAS G13C engagement, suggesting a role for wild-type RAS(ON). We find that codon 13-mutant RAS differs from other KRAS mutations, exhibiting decreased stability, increased nucleotide exchange, and substantial intrinsic and GAP-stimulated GTP hydrolysis, which decreases oncogenicity. Furthermore, co-occurring RAS pathway mutations leading to increased wild-type RAS activation are enriched in codon 13 mutant tumors. Consistent with a role for wild-type RAS(ON) signaling, combination of RMC-8839 with a RAS(ON) multi-selective inhibitor resulted in deeper inhibition of KRAS G13C-mutant xenograft tumor growth than either inhibitor alone.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Seamon KJ, Zhuang Y, Yang YC, et al. Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers. Cancer Discov. 2026. PMID: 42329095. doi:10.1158/2159-8290.CD-25-0886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。